Zhitong Finance App News, Kangyuan Pharmaceutical (600557.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” for Shiwei Gansu Granules issued by the State Drug Administration. Shiwei Intestinal Granules are clinical empirical formulations formed under the theoretical guidance of traditional Chinese medicine. They have the effects of strengthening the spleen, clearing the intestines, and relieving diarrhea, and are clinically used for ulcerative colitis caused by spleen deficiency.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.